Systematic review on fecal calprotectin in cystic fibrosis

Lazzarotto, Eduarda Sampaio; Vasco, Jannaina Ferreira de Melo; Führ, Fabiane; Riedi, Carlos Antônio; Filho, Nelson Augusto Rosário

doi:10.1016/j.jped.2022.01.006

Cited by 1 publication

(1 citation statement)

References 29 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in fecal calprotectin levels over time can indicate treatment efficacy and disease progression, guiding therapeutic interventions and optimizing patient care. Fecal calprotectin may also serve as a non-invasive tool for assessing intestinal inflammation in cystic fibrosis patients, reducing the need for invasive procedures such as endoscopy[ 150 ]. However, it's important to note that fecal calprotectin levels can be influenced by factors other than cystic fibrosis-related intestinal inflammation, such as infection, dietary factors, and certain medications, such as antibiotics[ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons

Al-Beltagi,

Saeed,

Bediwy

et al. 2024

World J Clin Pediatr

View full text Add to dashboard Cite

BACKGROUND Fecal calprotectin is a valuable biomarker for assessing intestinal inflammation in pediatric gastrointestinal diseases. However, its role, pros, and cons in various conditions must be comprehensively elucidated. AIM To explore the role of fecal calprotectin in pediatric gastrointestinal diseases, including its advantages and limitations. METHODS A comprehensive search was conducted on PubMed, PubMed Central, Google Scholar, and other scientific research engines until February 24, 2024. The review included 88 research articles, 56 review articles, six meta-analyses, two systematic reviews, two consensus papers, and two letters to the editors. RESULTS Fecal calprotectin is a non-invasive marker for detecting intestinal inflammation and monitoring disease activity in pediatric conditions such as functional gastrointestinal disorders, inflammatory bowel disease, coeliac disease, coronavirus disease 2019-induced gastrointestinal disorders, gastroenteritis, and cystic fibrosis-associated intestinal pathology. However, its lack of specificity and susceptibility to various confounding factors pose challenges in interpretation. Despite these limitations, fecal calprotectin offers significant advantages in diagnosing, monitoring, and managing pediatric gastrointestinal diseases. CONCLUSION Fecal calprotectin holds promise as a valuable tool in pediatric gastroenterology, offering insights into disease activity, treatment response, and prognosis. Standardized protocols and guidelines are needed to optimize its clinical utility and mitigate interpretation challenges. Further research is warranted to address the identified limitations and enhance our understanding of fecal calprotectin in pediatric gastrointestinal diseases.

show abstract

Section: Discussionmentioning

confidence: 99%